Risk, management of VTE in bevacizumab-treated colorectal cancer
the ONA take:
Risk of venous thromboembolisms (VTEs) in patients with cancer can be high, according to researchers in British Columbia, Canada. This patient population is already predisposed to prothrombotic states.
The researchers assessed the incidence of VTEs in a cohort of patients with metastatic colorectal cancer (mCRC) who were treated with bevacizumab.
Using a cohort of 499 evaluable patients, the researchers found 81 patients developed VTEs after receiving bevacizumab, and nine patients experienced more than one event. Those patients who experienced VTEs were more likely to have pre-existing cardiovascular diseases, resection of the primary cancer, high pre-chemotherapy platelet count, and received more than 12 bevacizumab cycles.
The researchers conclude the risk of VTEs can be high in patients receiving bevacizumab, especially in those with specific pretreatment risk factors and in those who received more of the drug.
Researchers assessed the incidence of VTEs in a cohort of patients with metastatic colorectal cancer (mCRC) who were treated with bevacizumab.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|